Phaseline

Companies › Green Cross

Green Cross: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 2; Infectious disease; next expected readout Jun 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
MG1111 (BARICELA)
Varicella-zoster virus vaccine
VZVPhase 2VaricellaJun 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05422508MG1111 (BARICELA)Phase 2VaricellaInfectious diseaseJun 2027

From the company's SEC filings

Complete response letters from FDA

Targets

VZV (1)

Companies with the same targets

MAXVAX Biotechnology Limited Liability Company Guangzhou Patronus Biotech

Companies built like this

Guangzhou Patronus Biotech Osivax Artcline Shanghai HEP Pharmaceutical BiomX

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.